title: [Flotation mass-spectra and surface potential of low density lipoprotein particles of hyperlipidemic patients after forced abolishment of lavostatin treatment].
abstract: The lipid status of lovastatin-treated hyperlipidemic patients with documented atherosclerosis of coronary arteries and carotid artery atheroma without signs of calcinosis significantly changed 4 weeks after termination of lovastatin therapy. LDL flotation mass-spectra were shown to be a sensitive indicator of variations of the lipid status. All LDL mass-spectra can be subdivided into four subfractions (from 12 to 32 S at solvent density of 1.170 g/ml and a step of 5 S). Taking into consideration previous data on total electronegative charge of LDL subfractions flotation mass-spectra indicate that lovastatin caused reduction of total negative surface charge of LDL by 1.8-fold mainly due to reduction of (17-22) and (22-27) S. However, in patients with high level of triglycerols reduction of LDL electronegative charge was due to decrease of cholesterol in (12-17) S subfraction. The latter consists of the smallest particles of the highest density. Combined analysis of similarity in lipid parameters and flotation mass-spectra of LDL allows recognizing rather homogenous groups of patients demonstrating similar responsiveness to lovastatin therapy.
authors.forename: A D
authors.initials: AD
authors.lastname: Morozkin
authors.forename: A B
authors.initials: AB
authors.lastname: Sumarokov
authors.forename: N V
authors.initials: NV
authors.lastname: Medvedeva
authors.forename: A A
authors.initials: AA
authors.lastname: Liakishev
mesh_terms: D000328:Adult; D002784:Cholesterol / Q000097:blood / Q000737:chemistry; D004563:Electrochemistry; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000097:blood* / Q000737:chemistry; D008148:Lovastatin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D013058:Mass Spectrometry / Q000379:methods; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood / Q000737:chemistry; D014461:Ultracentrifugation
chemical_list: D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D014280:Triglycerides; D002784:Cholesterol; D008148:Lovastatin